In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
September 26th, 2005 | 27 | No |
Popular Name: Finasteride Finasteride
Find On: PubMed — Wikipedia — Google
CAS Numbers: 1217547-06-2 , 98319-26-7 , [98319-26-7]
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-Butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,1
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
4-azaandrost-1-ene-17-carboxamide, N -(1,1-dimethylethyl)-3-oxo-,(5(alpha),17(beta))-
4-azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha, 17beta)-
4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)-
98319-26-7; D00321; Finasteride (JAN/USP/INN); Propecia (TN); Proscar (TN)
Cahill May Roberts Brand of Finasteride
Chibro-proscar;Finasterida;Finasteridum;Finastid;Finpecia;Propecia;Proscar;Prostide
CPD000466304; FINASTERIDE; 98319-26-7
CPD000466304; FINASTERIDE; SAM001246541
finasterida; finasteride; finasteridum
Frosst Iberica Brand of Finasteride
Merck Frosst Brand 1 of Finasteride
Merck Frosst Brand 2 of Finasteride
Merck Sharp & Dhome Brand 2 of Finasteride
Merck Sharp & Dohme Brand 1 of Finasteride
MSD Chibropharm Brand of Finasteride
N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide
N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 4.00 | 7.36 | -13.16 | 2 | 4 | 0 | 58 | 372.553 | 2 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
ALOGPS_SOLUBILITY | 1.98e-03 g/l | DrugBank-approved |
MP | 253 | TCI |
Target | 5-alpha Reductase | Selleck Chemicals |
Purity | 99% | Fluorochem |
Therapy | anti-androgen, alpha-reductase inhibitor | SMDC Pharmakon |
Indications | benign prostatic hyperplasia, male baldness | KeyOrganics Bioactives |
Indications | benign prostatic hyperplasia, male bladness | KeyOrganics Bioactives |
UniProt Database Links | DET2_SOLLC | ChEBI |
Patent Database Links | EP1262177; EP1364659; EP1574499; EP1580194; EP1623741; EP1743656; EP1790653; EP1832576; EP1939204; EP1988098; GB2346142; GB2355456; GB2355457; US2001020038; US2003229092; US2005009845; US2005101646; US2005124621; US2005159420; US2005187267; US2005192310 | ChEBI |
PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Sequoia Research Products Ltd.; NCC_SUPPLIER_STRUCTURE_ID : SRP00500f | NIH Clinical Collection via PubChem |
PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Sequoia Research Products Ltd.; SUPPLIER_STRUCTURE_ID: SRP00500f | NIH Clinical Collection via PubChem |
Purity | USP25 | APIChem |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
3BHS2-1-E | 3-beta-hydroxysteroid Dehydrogenase/delta 5-->4-isomerase Type II (cluster #1 Of 1), Eukaryotic | Eukaryotes | 150 | 0.35 | Binding ≤ 10μM |
3BHS5-1-E | 3-beta-hydroxysteroid Dehydrogenase Type III (cluster #1 Of 1), Eukaryotic | Eukaryotes | 150 | 0.35 | Binding ≤ 10μM |
S5A1-1-E | Steroid 5-alpha-reductase 1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 88 | 0.37 | Binding ≤ 10μM |
S5A2-1-E | Steroid 5-alpha-reductase 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 88 | 0.37 | Binding ≤ 10μM |
S5A1-1-E | Steroid 5-alpha-reductase 1 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 60 | 0.37 | Functional ≤ 10μM |
S5A2-1-E | Steroid 5-alpha-reductase 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 2100 | 0.29 | Functional ≤ 10μM |
Z50425-4-O | Plasmodium Falciparum (cluster #4 Of 22), Other | Other | 7943 | 0.26 | Functional ≤ 10μM |
Z80125-3-O | DU-145 (Prostate Carcinoma) (cluster #3 Of 9), Other | Other | 3900 | 0.28 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
3BHS5_RAT | P27364 | 3-beta-hydroxysteroid Dehydrogenase Type III, Rat | 150 | 0.35 | Binding ≤ 1μM |
3BHS2_RAT | P22072 | 3-beta-hydroxysteroid Dehydrogenase/delta 5-->4-isomerase Type II, Rat | 150 | 0.35 | Binding ≤ 1μM |
S5A1_RAT | P24008 | Steroid 5-alpha-reductase 1, Rat | 10 | 0.41 | Binding ≤ 1μM |
S5A1_HUMAN | P18405 | Steroid 5-alpha-reductase 1, Human | 150 | 0.35 | Binding ≤ 1μM |
S5A2_RAT | P31214 | Steroid 5-alpha-reductase 2, Rat | 0.28 | 0.50 | Binding ≤ 1μM |
S5A2_HUMAN | P31213 | Steroid 5-alpha-reductase 2, Human | 0.1 | 0.52 | Binding ≤ 1μM |
3BHS5_RAT | P27364 | 3-beta-hydroxysteroid Dehydrogenase Type III, Rat | 150 | 0.35 | Binding ≤ 10μM |
3BHS2_RAT | P22072 | 3-beta-hydroxysteroid Dehydrogenase/delta 5-->4-isomerase Type II, Rat | 150 | 0.35 | Binding ≤ 10μM |
S5A1_RAT | P24008 | Steroid 5-alpha-reductase 1, Rat | 10 | 0.41 | Binding ≤ 10μM |
S5A1_HUMAN | P18405 | Steroid 5-alpha-reductase 1, Human | 150 | 0.35 | Binding ≤ 10μM |
S5A2_RAT | P31214 | Steroid 5-alpha-reductase 2, Rat | 0.28 | 0.50 | Binding ≤ 10μM |
S5A2_HUMAN | P31213 | Steroid 5-alpha-reductase 2, Human | 0.1 | 0.52 | Binding ≤ 10μM |
Z80125 | Z80125 | DU-145 (Prostate Carcinoma) | 3900 | 0.28 | Functional ≤ 10μM |
Z50425 | Z50425 | Plasmodium Falciparum | 10000 | 0.26 | Functional ≤ 10μM |
S5A1_HUMAN | P18405 | Steroid 5-alpha-reductase 1, Human | 580 | 0.32 | Functional ≤ 10μM |
S5A2_RAT | P31214 | Steroid 5-alpha-reductase 2, Rat | 2100 | 0.29 | Functional ≤ 10μM |
S5A2_HUMAN | P31213 | Steroid 5-alpha-reductase 2, Human | 2 | 0.45 | Functional ≤ 10μM |
Description | Species |
---|---|
Androgen biosynthesis | |
Glucocorticoid biosynthesis | |
Mineralocorticoid biosynthesis |